Kyntra Bio (NASDAQ:KYNB) Releases Earnings Results

Kyntra Bio (NASDAQ:KYNB) posted its quarterly earnings results on Monday. The company reported ($3.51) EPS for the quarter, FiscalAI reports. The firm had revenue of $1.28 million during the quarter.

Kyntra Bio Stock Performance

KYNB traded up $0.03 during trading on Monday, hitting $7.00. The company’s stock had a trading volume of 20,597 shares, compared to its average volume of 31,881. Kyntra Bio has a twelve month low of $4.85 and a twelve month high of $12.60. The stock has a market cap of $28.35 million, a PE ratio of 0.13 and a beta of 0.84. The business has a 50 day simple moving average of $7.81.

Analysts Set New Price Targets

KYNB has been the subject of several research reports. Zacks Research cut Kyntra Bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Weiss Ratings initiated coverage on Kyntra Bio in a research note on Wednesday, January 14th. They set a “sell (d+)” rating for the company. Finally, HC Wainwright upgraded shares of Kyntra Bio to a “strong-buy” rating in a research report on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Kyntra Bio has an average rating of “Hold”.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.